

# Antihypertensives: Global Markets to 2023

<https://marketpublishers.com/r/A0F0276DE5AEN.html>

Date: January 2019

Pages: 144

Price: US\$ 1,375.00 (Single User License)

ID: A0F0276DE5AEN

## Abstracts

### Report Scope:

The current report offers a detailed analysis of the antihypertensive drug market. The study includes a discussion of antihypertensive drugs prescribed for lowering the high blood pressure and for the treatment of pulmonary arterial hypertension (PAH). The report excludes drugs used in the treatment of ocular hypertension. The market size includes both branded and generic drugs.

The report highlights the current and future market potential of antihypertensive drugs and provides a detailed analysis of the competitive environment, regulatory scenario, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players.

The report details market shares of antihypertensive drugs based on drug class and geography. Based on drug class, the market is segmented into ACE inhibitors (angiotensin-converting enzyme inhibitors), ARBs (angiotensin II receptor blockers), beta blockers, calcium channel blockers, diuretics, combination drugs, and others (a segment that includes direct renin inhibitors, alpha blockers, PDE-5 inhibitors, stimulators of soluble guanylate cyclase, endothelin receptor antagonists, vasodilators, and prostacyclin receptors).

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2017 as the base year, with forecasts for 2018 through 2023. Estimated values are based on drug manufacturers' total revenues. Projected and

forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

#### Report Includes:

67 tables

Country specific data and analysis for France, Germany, Italy, U.K., Spain, Russia, India, China, Japan, United States, Canada, Middle East and Africa

A brief study of current and future market potential of antihypertensive drugs along with a detailed analysis of the competitive environment

Exposure to the industry driven underlying markets, government regulations, and technology updates

Coverage of regulatory dynamics, pipeline analysis, patent analysis, and market drivers, restrains, and opportunities

Company profiles of major manufacturers, suppliers, and supply chain participants, including Allergan Plc, Boehringer Ingelheim GMBH, Johnson & Johnson, Daiichi Sankyo Co. Ltd, Pfizer Inc. and Novartis AG

## Contents

### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives  
Reasons for Doing This Study  
Scope of Report  
Information Sources  
Methodology  
Geographic Breakdown  
Analysts' Credentials  
BCC Custom Research  
Related BCC Research Reports

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

### **CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND**

Hypertension  
Pathophysiology and Pathogenesis  
Classification  
Prevalence of Hypertension  
Antihypertensive Drugs  
Commonly Prescribed Antihypertensive Drugs  
Side Effects of Antihypertensive Drugs  
Contraindications of Major Antihypertensive Drugs  
Resistant Hypertension

### **CHAPTER 4 MARKET DYNAMICS**

Growth Drivers  
Increasing Prevalence of Hypertension  
Rising Geriatric Population and Government Assistance for Prescription Drugs  
Sedentary Lifestyle: Contributing Significantly toward High Risk of Hypertension  
Improved Awareness of Hypertension: Earlier Diagnosis and Treatment  
Market Restraints  
Patent Expirations of Branded Drugs  
Drug Development Process: High Cost and Pricing Pressures  
Market Opportunities

Patent Expiration: Growth Opportunities for Generic Players  
Unmet Needs in Low- and Middle-Income Countries

## **CHAPTER 5 MARKET BREAKDOWN BY DRUG CLASS**

Global Antihypertensive Drug Market  
Angiotensin-Converting Enzyme (ACE) Inhibitors  
Market Size and Forecast  
Market Analysis  
Angiotensin II Receptor Blockers  
Market Size and Forecast  
Market Analysis  
Beta Blockers  
Market Size and Forecast  
Market Analysis  
Calcium Channel Blockers  
Market Size and Forecast  
Market Analysis  
Diuretics  
Market Size and Forecast  
Market Analysis  
Combination Drug  
Market Size and Forecast  
Market Analysis  
Others  
Market Size and Forecast  
Market Analysis

## **CHAPTER 6 MARKET BREAKDOWN BY REGION**

Global Market for Antihypertensives by Region  
North America  
United States  
Canada  
Mexico  
Europe  
Germany  
France  
&^%\$fghj U.K.

Italy  
Spain  
Rest of Europe  
Asia-Pacific  
Japan  
China  
India  
Rest of Asia-Pacific  
South America  
Market Size and Forecast  
Market Analysis  
Middle East and Africa  
Market Size and Forecast  
Market Analysis

## **CHAPTER 7 REGULATORY ENVIRONMENT**

Regulations in the U.S.  
New Drug Approvals  
The FDA Modernization Act of 1997  
Fast-Track Status  
Special Protocol Assessments  
Medicare  
Principles for Clinical Evaluation of New Antihypertensive Drugs  
Hypertension Guidelines in the U.S.  
Regulations in Europe  
Hypertension Guidelines in Europe  
Pricing and Reimbursement  
Regulations in Asia-Pacific  
Regulations in Japan  
Regulations in China  
Regulations in India

## **CHAPTER 8 PATENT ANALYSIS**

Patent Length and Market Exclusivity

## **CHAPTER 9 PIPELINE ANALYSIS**

Overview of the Drug Development Process  
Pipeline Analysis of Antihypertensive Drugs  
Antihypertensive Drugs in Phase I Clinical Trials  
Antihypertensive Drugs in Phase II Clinical Trials  
Antihypertensive Drugs in Phase III Clinical Trials  
Late-Stage Pipeline Drugs

## **CHAPTER 10 COMPETITIVE LANDSCAPE**

Global Company Share Analysis  
Mergers and Acquisitions  
Agreements, Collaborations, and Partnerships  
Impact of Generic Antihypertensives on the Market

## **CHAPTER 11 COMPANY PROFILES**

&^%\$fghj ALLERGAN PLC

Company Overview

Business Performance

Products Offered

Developments and Strategies

&^%\$fghj ASTELLAS PHARMA INC.

Company Overview

Products Offered

Developments and Strategies

&^%\$fghj ARBOR PHARMACEUTICALS LLC

Company Overview

Products Offered

&^%\$fghj ASTRAZENECA PLC

Company Overview

Business Performance

AstraZeneca plc Business Segment Revenue

AstraZeneca Plc Revenue by Region Segment

Product Portfolio

Developments and Strategies

&^%\$fghj BAYER AG

Company Overview

Business Performance

Products Offered

Developments and Strategies  
&^%\$fghj BOEHRINGER INGELHEIM GMBH

Company Overview

Business Performance

Products Offered

Developments and Strategies

&^%\$fghj DAIICHI SANKYO CO. LTD.

Company Overview

Business Performance

Products Offered

Developments and Strategies

&^%\$fghj ELI LILLY AND CO.

Company Overview

Products Offered

Developments and Strategies

&^%\$fghj GILEAD SCIENCES INC.

Company Overview

Business Performance

Products Offered

Developments and Strategies

&^%\$fghj GLAXOSMITHKLINE PLC

Company Overview

Products Offered

Developments and Strategies

&^%\$fghj HIKMA PHARMACEUTICALS PLC

Company Overview

Products Offered

&^%\$fghj JOHNSON & JOHNSON

Company Overview

Business Performance

Product Portfolio

Developments and Strategies

&^%\$fghj LUPIN LTD.

Company Overview

Product Portfolio

&^%\$fghj MERCK & CO. INC.

Company Overview

Products Offered

Developments and Strategies

&^%\$fghj NOVARTIS AG

Company Overview

Business Performance

Products Offered

Developments and Strategies

&^%\$fghj PFIZER INC.

Company Overview

Business Performance

Products Offered

Developments and Strategies

&^%\$fghj SANOFI

Company Overview

Business Performance

Products Offered

Developments and Strategies

&^%\$fghj TAKEDA PHARMACEUTICAL CO. LTD.

Company Overview

Product Portfolio

&^%\$fghj TEVA PHARMACEUTICAL INDUSTRIES LTD.

Company Overview

Products Offered

&^%\$fghj UNITED THERAPEUTICS CORP.

Company Overview

Business Performance

Products Offered

Developments and Strategies

## **CHAPTER 12 APPENDIX: ACRONYMS**



## List Of Tables

### LIST OF TABLES

Summary Table: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023

Table 1: Classification of Hypertension or Blood Pressure

Table 2: Global Prevalence of Hypertension with Population Aged 18 Years or Older, by Country, 2015

Table 3: Commonly Prescribed Antihypertensive Drugs

Table 4: Side Effects with Different Classes of Antihypertensive Drugs

Table 5: Contraindications of Major Antihypertensive Drugs

Table 6: Prevalence of High Blood Pressure, by Gender and Age Group, U.S., 2016

Table 7: Prevalence Rates of Obesity for Male and Female in Australia, 1995-2015

Table 8: Patent Expiration Dates for Antihypertensive Drugs, 2016-2018\*

Table 9: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023

Table 10: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, Through 2023

Table 11: ACE Inhibitors Drug, Branded/Generic FDA Approval

Table 12: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, Through 2023

Table 13: Global Market for Beta Blocker Drugs, by Region, Through 2023

Table 14: Global Market for Calcium Channel Blocker Drugs, by Region, Through 2023

Table 15: Global Market for Diuretics Drugs, by Region, Through 2023

Table 16: Global Market for Combination Drugs, by Region, Through 2023

Table 17: Commonly Prescribed Combinations of Antihypertensive Drugs

Table 18: Global Market for Other Antihypertensive Drugs, by Region, Through 2023

Table 19: Commonly Prescribed Types of Other Antihypertensive Drugs

Table 20: Global Market for Antihypertensive Drugs, by Region, Through 2023

Table 21: North American Market for Antihypertensive Drugs, by Drug Class, Through 2023

Table 22: North American Market for Antihypertensive Drugs, by Country, Through 2023

Table 23: Total Number of High Blood Pressure Patients in Canada, by Age Group, 2016 and 2017

Table 24: European Market for Antihypertensive Drugs, by Drug Class, Through 2023

Table 25: European Market for Antihypertensive Drugs, by Country, Through 2023

Table 26: Asia-Pacific Market for Antihypertensive Drugs, by Drug Class, Through 2023

Table 27: Asia-Pacific Market for Antihypertensive Drugs, by Country, Through 2023

Table 28: South American Market for Antihypertensive Drugs, by Drug Class, Through

2023

Table 29: Middle Eastern and African Market for Antihypertensive Drugs, by Drug Class, Through 2023

Table 30: Arbor Pharmaceuticals LLC: Antihypertensives Patent Exclusivity

Table 31: Allergan Plc: Antihypertensives Patent Exclusivity

Table 32: Chiesi USA Inc.: Antihypertensives Patent Exclusivity

Table 33: Eli Lilly and Co.: Antihypertensives Patent Exclusivity

Table 34: Gilead Sciences Inc.: Antihypertensives Patent Exclusivity

Table 35: GlaxoSmithKline plc: Antihypertensives Patent Exclusivity

Table 36: Novartis AG: Antihypertensives Patent Exclusivity

Table 37: Noden Pharma DAC: Antihypertensives Patent Exclusivity

Table 38: Johnson & Johnson: Antihypertensives Patent Exclusivity

Table 39: United Therapeutics Corp.: Antihypertensives Patents Exclusivity

Table 40: Other Applicants: Antihypertensives Patent Exclusivity

Table 41: Exclusivity Expiration of Antihypertensive Drugs

Table 42: Preclinical & Phase I Pipeline of Antihypertensive Drugs

Table 43: Phase II Pipeline of Antihypertensive Drugs

Table 44: Phase III Pipeline of Antihypertensive Drugs

Table 45: Generic Launches in the Antihypertensive Market, 2015-2018

Table 46: Allergan Plc: Antihypertensive Drugs Product Portfolio

Table 47: Astellas Pharma Inc.: Antihypertensive Drugs Product Portfolio

Table 48: Arbor Pharmaceutical LLC.: Antihypertensive Drugs Product Portfolio

Table 49: AstraZeneca Plc: Antihypertensive Drugs Product Portfolio

Table 50: Bayer AG: Antihypertensive Drugs Product Portfolio

Table 51: Boehringer Ingelheim GmbH: Antihypertensive Drugs Product Portfolio

Table 52: Daiichi Sankyo Co. Ltd.: Antihypertensive Drugs Product Portfolio

Table 53: Eli Lilly and Co.: Antihypertensive Drugs Product Portfolio

Table 54: Gilead Science Inc.: Antihypertensive Drugs Product Portfolio

Table 55: GlaxoSmithKline Plc: Antihypertensive Drugs Product Portfolio

Table 56: Hikma Pharmaceuticals Plc: Antihypertensive Drugs Product Portfolio

Table 57: Johnson & Johnson: Antihypertensive Drugs Product Portfolio

Table 58: Lupin Ltd.: Antihypertensive Drugs Product Portfolio

Table 59: Merck & Co. Inc.: Antihypertensive Drugs Product Portfolio

Table 60: Novartis AG: Antihypertensive Drugs Product Portfolio

Table 61: Pfizer Inc.: Antihypertensive Drugs Product Portfolio

Table 62: Sanofi: Antihypertensive Drugs Product Portfolio

Table 63: Takeda Pharmaceutical.: Antihypertensive Drugs Product Portfolio

Table 64: Teva Pharmaceutical Industries Ltd.: Antihypertensive Drugs Product Portfolio

Table 65: United Therapeutics Corp.: Antihypertensive Drugs Product Portfolio

Table 66: Acronyms Used in This Report

## List Of Figures

### LIST OF FIGURES

Summary Figure: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017

Figure 1: Prevalence of Hypertension Among U.S. Adults Aged 18 and Older, by Sex and Age, 2016

Figure 2: Prevalence Rates for Adult Obesity, by Country, 2016

Figure 3: Diovan/Co-Diovan Revenue, 2013-2017

Figure 4: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017

Figure 5: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, 2017-2023

Figure 6: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, 2017-2023

Figure 7: Global Market for Angiotensin II Receptor Blockers (ARBs), 2017-2023

Figure 8: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, 2017-2023

Figure 9: Leading ARBs Drug Prescriptions in the U.S., 2016

Figure 10: Global Market for Beta Blocker Drugs, 2017-2023

Figure 11: Global Market for Beta Blocker Drugs, by Region, 2017-2023

Figure 12: Global Market for Calcium Channel Blocker Drugs, 2017-2023

Figure 13: Global Market for Calcium Channel Blocker Drugs, by Region, 2017-2023

Figure 14: Global Market for Diuretics Drugs, 2017-2023

Figure 15: Global Market for Diuretics Drugs, by Region, 2017-2023

Figure 16: Global Market for Combination Drugs, 2017-2023

Figure 17: Global Market for Combination Drugs, by Region, 2017-2023

Figure 18: Global Market for Other Antihypertensive Drugs, 2017-2023

Figure 19: Global Market for Other Antihypertensive Drugs, by Region, 2017-2023

Figure 20: Global Market Share for Antihypertensive Drugs, by Region, 2017

Figure 21: North American Market Share for Antihypertensive Drugs, by Drug Class, 2017

Figure 22: North American Market Share for Antihypertensive Drugs, by Country, 2017

Figure 23: U.S. Market for Antihypertensive Drugs, 2017-2023

Figure 24: Canadian Market for Antihypertensive Drugs, 2017-2023

Figure 25: Mexican Market for Antihypertensive Drugs, 2017-2023

Figure 26: European Market Share for Antihypertensive Drugs, by Drug Class, 2017

Figure 27: European Market Share for Antihypertensive Drugs, by Country, 2017

Figure 28: German Market for Antihypertensive Drugs, 2017-2023

Figure 29: French Market for Antihypertensive Drugs, 2017-2023

- Figure 30: U.K. Market for Antihypertensive Drugs, 2017-2023
- Figure 31: Italian Market for Antihypertensive Drugs, 2017-2023
- Figure 32: Spanish Market for Antihypertensive Drugs, 2017-2023
- Figure 33: Rest of Europe Market for Antihypertensive Drugs, 2017-2023
- Figure 34: Asia-Pacific Market Share for Antihypertensive Drugs, by Drug Class, 2017
- Figure 35: Asia-Pacific Market Share for Antihypertensive Drugs, by Country, 2017
- Figure 36: Japanese Market for Antihypertensive Drugs, 2017-2023
- Figure 37: Chinese Market for Antihypertensive Drugs, 2017-2023
- Figure 38: Indian Market for Antihypertensive Drugs, 2017-2023
- Figure 39: Rest of Asia-Pacific Market for Antihypertensive Drugs, 2017-2023
- Figure 40: South American Market for Antihypertensive Drugs, 2017-2023
- Figure 41: South American Market Share for Antihypertensive Drugs, by Drug Class, 2017
- Figure 42: Middle Eastern and African Market for Antihypertensive Drugs, 2017-2023
- Figure 43: Middle East and African Market Share for Antihypertensive Drugs, by Drug Class, 2017
- Figure 44: China CFDA Drug Regulatory Approval Process
- Figure 45: Global Antihypertensive Drug Market Share, by Manufacturer, 2017
- Figure 46: Novartis AG: Sales Revenue for Co-Diovan/Diovan HCT, 2014-2017
- Figure 47: Allergan Plc: Annual Revenue, 2013-2017
- Figure 48: Allergan Plc: Revenue Share, by Business Unit, 2017
- Figure 49: AstraZeneca Plc: Annual Revenue, 2013-2017
- Figure 50: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
- Figure 51: AstraZeneca Plc: Revenue Share, by Region, 2017
- Figure 52: Bayer AG: Annual Revenue, 2013-2017
- Figure 53: Bayer AG: Revenue Share, by Region, 2017
- Figure 54: Boehringer Ingelheim GmbH: Annual Revenue, 2013-2017
- Figure 55: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
- Figure 56: Daiichi Sankyo Co. Ltd.: Annual Revenue, 2015-2017
- Figure 57: Gilead Sciences Inc.: Annual Revenue, 2014-2017
- Figure 58: Johnson & Johnson: Annual Revenue, 2013-2017
- Figure 59: Johnson & Johnson: Revenue Share, by Region, 2017
- Figure 60: Johnson & Johnson: Revenue Share, by Business Unit, 2017
- Figure 61: Novartis AG.: Annual Revenue, 2013-2017
- Figure 62: Novartis AG: Revenue Share, by Region, 2017
- Figure 63: Novartis AG: Revenue Share, by Business Segment, 2017
- Figure 64: Pfizer Inc.: Annual Revenue, 2013-2017
- Figure 65: Pfizer Inc.: Revenue Share, by Region, 2017
- Figure 66: Pfizer Inc.: Revenue Share, by Business Segment, 2017

Figure 67: Sanofi.: Annual Revenue, 2013-2017

Figure 68: Sanofi: Revenue Share, by Region, 2017

Figure 69: United Therapeutics Corp: Annual Revenue, 2015-2017

## I would like to order

Product name: Antihypertensives: Global Markets to 2023

Product link: <https://marketpublishers.com/r/A0F0276DE5AEN.html>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A0F0276DE5AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970